biomarkers
NeurologyLive: The Study Design Behind P-tau217 Rule-In Performance
August 3, 2026Author(s)Yogesh Shah, MD, MPH, FAAFP Dr. Yogesh Shah, MD, reviews the evidence supporting P-tau217 as a reliable rule-in biomarker for Alzheimer’s pathology and discusses how clinicians can incorporate blood-based testing into patient evaluation.As blood-based biomarkers move closer to routine clinical use, demonstrating agreement with established diagnostic standards remains essential. For Alzheimer disease (AD), […]
Breaking Barriers: New Findings on Biomarkers and Expanding Participation in Alzheimer’s Research
GAP Experts Share Poster Presentations at Alzheimer’s Association International Conference (AAIC) Washington D.C., July 9, 2026- The Global Alzheimer’s Platform Foundation®, (GAP) will have two poster presentations at the 2026 Alzheimer’s Association International Conference (AAIC) being held in Londong July 12 through July 15. All posters are in the Exhibit Hall in Excel London, Royal Victoria Dock, 1 […]
GAP Applauds the Decision by Elevance Health to Explicitly Endorse the Use of Blood-Based Biomarker Testing
Washington D.C., July 1, 2026- Elevance Health, formerly Anthem Inc., updated their medical policy, to allow for blood-based biomarker testing for the detection and diagnosis of Alzheimer’s disease, making Elevance Health one of the first major payors to outline coverage criteria. GAP President John Dwyer said, “GAP applauds the decision by Elevance Health to explicitly endorse […]
TrialSite News: Exploring Circular RNA Biomarkers in Alzheimer’s Research
John Dwyer, the President of the Global Alzheimer’s Platform Foundation (GAP) joins TrialSiteNews to discuss a collaboration and partnership with Circular Genomics. The partnership will analyze blood test samples to investigate the potential for circular RNA biomarkers to assist in the diagnosis & treatment of Alzheimer’s Disease. Topics covered: Press Release: https://globalalzplatform.org/2026/05…
TrialSite News: Alzheimer’s Diagnostics Race Accelerates as Global Alzheimer’s Platform Expands Bio-Hermes-002 Study
TrialSite Staff | Making Biomedical Research Evidence Accessible to All May. 18, 2026, 2:30 p.m. The global battle against Alzheimer’s disease may increasingly hinge on one critical factor: detecting the disease earlier, faster, and more accurately before irreversible neurological decline takes hold. This week, the Global Alzheimer’s Platform Foundation (GAP) announced the continued expansion of its Bio-Hermes-002 […]
Global Alzheimer’s Platform Foundation Announces Strategic Collaboration and Partnership for the Transformative Bio-Hermes-002 Study
Bio-Hermes-002 is a collaborative study focused on new biomarkers designed to improve diagnosis of Alzheimer’s disease and dementias. Washington D.C., May 18, 2026 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce the continued expansion of the Bio-Hermes-002 study, a unique observational platform study, which evaluates blood-based and digital biomarkers across a wide spectrum of cognitive conditions, alongside MRI and PET imaging and diverse […]
TrialSite News: Could a Blood Test Detect Alzheimer’s Earlier Than Brain Scans?
Could Alzheimer’s disease one day be detected with a simple blood test instead of expensive brain scans? In this episode of the TrialSite News Farago Podcast, we speak with John Dwyer, President and CEO of the Global Alzheimer’s Platform Foundation (GAP), about the Bio-Hermes-002 study and the future of Alzheimer’s detection. The conversation explores how […]
Knowridge: A simple blood test could reveal Alzheimer’s early
By Knowridge -March 25, 2026Alzheimer’s disease is one of the most common causes of memory loss in older adults. It slowly affects the brain, making it harder for people to remember things, think clearly, and carry out daily activities. As the global population ages, more and more families are facing the challenges of this condition. Because of […]
Medical Product Outsourcing: Could a Finger Prick Blood Test Help Diagnose Alzheimer’s?
The disease currently is diagnosed using expensive scans and lumbar punctures or spinal taps. February 18, 2026 By: Michael Barbella Managing Editor Alzheimer’s disease detection could be quite literally at our fingertips. A major international research project is underway at the U.K. Dementia Research Institute (DRI) to test whether a finger prick-style blood test could be […]
Providence Journal: Could a blood test detect Alzheimer’srisk? A RI company wants to know.
Diagnosing the disease can be expensive, invasive and complicated. Research in RI could help speed up the process Feb. 5, 2026, 5:04 a.m. ETEAST PROVIDENCE – Alzheimer’s, a neurodegenerative disease, is the primary cause of dementia in the United States. In Rhode Island, more than one in 10 adults over age 65 – about 22,000 […]